Couch RB, Winokur P, Edwards KM, Black S, Atmar RL, Stapleton JT, et al. Reducing the dose of smallpox vaccine reduces vaccine-associated morbidity without reducing vaccination success rates or immune responses. J Infect Dis. Mar 15 2007;195(6):826-32. [Medline].
Rimmelzwaan GF, Sutter G. Candidate influenza vaccines based on recombinant modified vaccinia virus Ankara. Expert Rev Vaccines. Apr 2009;8(4):447-54. [Medline].
Tykodi SS, Thompson JA. Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer. Expert Opin Biol Ther. Dec 2008;8(12):1947-53. [Medline].
Perera LP, Waldmann TA, Mosca JD, Baldwin N, Berzofsky JA, Oh SK. Development of smallpox vaccine candidates with integrated interleukin-15 that demonstrate superior immunogenicity, efficacy, and safety in mice. J Virol. Aug 2007;81(16):8774-83. [Medline].
Wertheimer ER, Olive DS, Brundage JF, Clark LL. Contact transmission of vaccinia virus from smallpox vaccinees in the United States, 2003-2011. Vaccine. Dec 19 2011;[Medline].
Redfield RR, Wright DC, James WD. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N Engl J Med. Mar 12 1987;316(11):673-6. [Medline].
Artenstein AW. New generation smallpox vaccines: a review of preclinical and clinical data. Rev Med Virol. Jul-Aug 2008;18(4):217-31. [Medline].
Baxby D. Indications for smallpox vaccination: policies still differ. Vaccine. 1993;11(4):395-6. [Medline].
Breman JG, Henderson DA. Diagnosis and management of smallpox. N Engl J Med. Apr 25 2002;346(17):1300-8. [Medline].
Buller RM, Palumbo GJ. Poxvirus pathogenesis. Microbiol Rev. Mar 1991;55(1):80-122. [Medline].
Carroll MW, Moss B. Poxviruses as expression vectors. Curr Opin Biotechnol. Oct 1997;8(5):573-7. [Medline].
[Guideline] Casey C, Vellozzi C, Mootrey GT, Chapman LE, McCauley M, Roper MH. Surveillance guidelines for smallpox vaccine (vaccinia) adverse reactions. MMWR Recomm Rep. Feb 3 2006;55(RR-1):1-16. [Medline].
Casey CG, Iskander JK, Roper MH, Mast EE, Wen XJ, Török TJ. Adverse events associated with smallpox vaccination in the United States, January-October 2003. JAMA. Dec 7 2005;294(21):2734-43. [Medline].
Clark J, Diven D. Poxviruses. In: Tyring S, Moore A, Lupi O, eds. Mucocutaneous Manifestations of Viral Diseases. 2nd ed. New York, NY: Informa HealthCare; In press.
Damon I. Orthopoxviruses: Vaccinia (Smallpox Vaccine), Variola (Smallpox), Monkeypox, and Cowpox. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 6th ed. Orlando, FL: Churchill Livingstone; 2005:1742-55.
Egan C, Kelly CD, Rush-Wilson K, Davis SW, Samsonoff WA, Pfeiffer H. Laboratory-confirmed transmission of vaccinia virus infection through sexual contact with a military vaccinee. J Clin Microbiol. Nov 2004;42(11):5409-11. [Medline].
Franz DR, Jahrling PB, Friedlander AM, McClain DJ, Hoover DL, Bryne WR, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA. Aug 6 1997;278(5):399-411. [Medline].
Friedman HM. Smallpox, Vaccinia, and Other Poxviruses. In: Isselbacher, et al, eds. Harrison's Principles of Internal Medicine. 13th ed. New York, NY: McGraw-Hill; 1994:798-9.
Grabenstein JD, Winkenwerder W Jr. US military smallpox vaccination program experience. JAMA. Jun 25 2003;289(24):3278-82. [Medline].
Haga IR, Bowie AG. Evasion of innate immunity by vaccinia virus. Parasitology. 2005;130 Suppl:S11-25. [Medline].
Harrop R, Ryan MG, Golding H, Redchenko I, Carroll MW. Monitoring of human immunological responses to vaccinia virus. Methods Mol Biol. 2004;269:243-66. [Medline].
Hopkins RJ, Lane JM. Clinical efficacy of intramuscular vaccinia immune globulin: a literature review. Clin Infect Dis. Sep 15 2004;39(6):819-26. [Medline].
Lane HC, Fauci AS. Microbial bioterrorism. In: Kasper, et al, eds. Harrison's Principles of Internal Medicine. 16th ed. New York, NY: McGraw-Hill; 2005.
Lane JM, Millar JD. Risks of smallpox vaccination complications in the United States. Am J Epidemiol. Apr 1971;93(4):238-40. [Medline].
Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968. N Engl J Med. Nov 27 1969;281(22):1201-8. [Medline].
Lewis FS, Norton SA, Bradshaw RD, Lapa J, Grabenstein JD. Analysis of cases reported as generalized vaccinia during the US military smallpox vaccination program, December 2002 to December 2004. J Am Acad Dermatol. Jul 2006;55(1):23-31. [Medline].
Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci U S A. Oct 15 1996;93(21):11341-8. [Medline].
Moss B. Poxvirus entry and membrane fusion. Virology. Jan 5 2006;344(1):48-54. [Medline].
Moss B. Vaccinia virus: a tool for research and vaccine development. Science. Jun 21 1991;252(5013):1662-7. [Medline].
Neff JM. Vaccinia Virus (Cowpox). In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 5th ed. Philadelphia, Pa: Churchill Livingstone; 2000:1553-5.
Notice to Readers: Newly Licensed Smallpox Vaccine to Replace Old Smallpox Vaccine. MMWR Morb Mortal Wkly. 2008;57:207-208.
Ojeda S, Domi A, Moss B. Vaccinia virus G9 protein is an essential component of the poxvirus entry-fusion complex. J Virol. Oct 2006;80(19):9822-30. [Medline].
Paoletti E. Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci U S A. Oct 15 1996;93(21):11349-53. [Medline].
Rotz LD, Dotson DA, Damon IK, Becher JA. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. MMWR Recomm Rep. Jun 22 2001;50:1-25; quiz CE1-7. [Medline].
Savona MR, Dela Cruz WP, Jones MS, Thornton JA, Xia D, Hadfield TL, et al. Detection of vaccinia DNA in the blood following smallpox vaccination. JAMA. Apr 26 2006;295(16):1898-900. [Medline].
Sejvar JJ, Labutta RJ, Chapman LE, Grabenstein JD, Iskander J, Lane JM. Neurologic adverse events associated with smallpox vaccination in the United States, 2002-2004. JAMA. Dec 7 2005;294(21):2744-50. [Medline].
Sepkowitz KA. How contagious is vaccinia?. N Engl J Med. Jan 30 2003;348(5):439-46. [Medline].
Stanley SL Jr, Frey SE, Taillon-Miller P, Guo J, Miller RD, Koboldt DC, et al. The immunogenetics of smallpox vaccination. J Infect Dis. Jul 15 2007;196(2):212-9. [Medline].
Stark JH, Frey SE, Blum PS, Monath TP. Lack of transmission of vaccinia virus. Emerg Infect Dis. Apr 2006;12(4):698-700. [Medline].
Townsley AC, Moss B. Two distinct low-pH steps promote entry of vaccinia virus. J Virol. Aug 2007;81(16):8613-20. [Medline].
| Complication | Number of cases from 450,293 vaccinations administered between 12/13/2002 and 5/28/2003 | Department of Defense rate per million vaccinees (95% confidence interval) | Historical number of cases from 1950s and 1960s |
| Death | 0 | 0 (0-3.7) | Age 1 y at first vaccination - 5 per 1 million primary vaccinees |
| Age 1-4 y at first vaccination - 0.5 per 1 million primary vaccinees | |||
| Age 5-19 y at first vaccination - 0.5 per 1 million primary vaccinees | |||
| Age ≥ 20 y at first vaccination - No data | |||
| Encephalitis | 1 | 2.2 (0.6-7.2) | 3 per 1 million primary vaccinees |
| Vaccinia necrosum/progressive vaccinia | 0 | 0 (0-3.7) | Approximately 1 patient per million during primary or revaccination |
| Usually fatal over a period of several months | |||
| Eczema vaccinatum | 0 | 0 (0-3.7) | 1 per 100,000 primary vaccinees |
| 1 per 1 million revaccinees | |||
| Generalized vaccinia | 36 | 80 (63-100) | Occasional occurrence in immunocompetent individuals |
| 3 per 100,000 primary vaccinees | |||
| 1 per 1 million revaccinees | |||
| Accidental vaccinia | 48 | 107 (88-129) | 3 per 100,000 to 1 million vaccinees |
| Erythematous rash | 36 | 80 (63-100) | Approximately 1 per 100,000 primary vaccinees* |
| Acute myopericarditis | 37 | 82 (65-102) | 100 per 1 million vaccinees |
| *Incidence was slightly higher when vaccination occurred before age 1 year. | |||

